Liquidia (NASDAQ:LQDA) Announces Earnings Results

Key Points

• Liquidia reported $171.7 million in quarterly revenue, up 1,842% year over year and above analyst estimates, while EPS of $0.74 narrowly missed the $0.76 consensus.
• YUTREPIA drove strong commercial growth, generating $170.4 million in net product sales, approximately 5,900 prescriptions and more than 5,000 patients. Management reported $74.7 million in net income, $96.3 million in adjusted EBITDA and $284.2 million in cash.
• The company plans to expand R&D across 10 YUTREPIA and L606 studies, but faces uncertainty from a pending ’327 litigation ruling that could result in royalties or injunctive relief.

Liquidia (NASDAQ:LQDA - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02), FiscalAI reports. The business had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm's revenue for the quarter was up 1842.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.49) earnings per share.

Here are the key takeaways from Liquidia's conference call:

• YUTREPIA continued strong commercial growth, with approximately 5,900 unique prescriptions, more than 5,000 patients started, and over 1,100 prescribing physicians as of July 31. Q2 net product sales reached $170.4 million, up 31% sequentially, and YUTREPIA represented nearly 30% of the inhaled treprostinil market.
• Liquidia reported improving profitability and cash generation, including $74.7 million of net income, $96.3 million of adjusted EBITDA, and $284.2 million in cash and equivalents. Management reiterated confidence in exceeding $1 billion in net revenue in 2027 while continuing to fund pipeline investments.
• The company is expanding its commercial organization and believes substantial opportunity remains in community-based PAH and PH-ILD diagnosis and treatment, as well as switches from competing inhaled, oral, and parenteral prostacyclin therapies. Payer access was described as broadly available and generally at parity.
• Liquidia plans significant R&D expansion, with second-half 2026 R&D expense expected to be double the first half and additional increases anticipated in 2027. The company has 10 YUTREPIA and L606 studies underway or planned, including the Phase III RESPIRE trial for twice-daily L606 and future studies in Raynaud’s phenomenon and progressive pulmonary fibrosis.
• The company is still awaiting a decision in the ’327 litigation, with management saying a ruling could come at any time and acknowledging possible outcomes including royalties or injunctive relief if the decision goes against Liquidia.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded down $1.41 during midday trading on Wednesday, hitting $86.64. The company's stock had a trading volume of 1,558,714 shares, compared to its average volume of 1,765,703. The company has a market cap of $7.70 billion, a P/E ratio of 618.90 and a beta of 0.58. Liquidia has a 12-month low of $21.15 and a 12-month high of $93.61. The business's 50 day simple moving average is $77.76 and its 200 day simple moving average is $54.51. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Analyst Ratings Changes

LQDA has been the topic of a number of research analyst reports. Oppenheimer set a $75.00 price target on shares of Liquidia in a research note on Friday, June 5th. Wall Street Zen lowered shares of Liquidia from a "strong-buy" rating to a "buy" rating in a research report on Saturday, June 27th. Raymond James Financial reissued a "strong-buy" rating and set a $68.00 target price on shares of Liquidia in a research note on Thursday, June 4th. BTIG Research lifted their price objective on Liquidia from $59.00 to $109.00 and gave the stock a "buy" rating in a report on Monday, June 22nd. Finally, Wells Fargo & Company boosted their price objective on Liquidia from $51.00 to $62.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Liquidia currently has an average rating of "Moderate Buy" and a consensus target price of $86.18.

Insider Activity at Liquidia

In other Liquidia news, insider Sanjeev Khindri sold 1,185 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $84,739.35. Following the completion of the sale, the insider owned 65,947 shares in the company, valued at approximately $4,715,869.97. This represents a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Dana Boyle sold 1,600 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $140,048.00. Following the completion of the transaction, the chief accounting officer directly owned 167,919 shares in the company, valued at $14,697,950.07. This trade represents a 0.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,781,861 shares of company stock worth $124,407,112 in the last 90 days. 25.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Liquidia

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in Liquidia by 428.3% in the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company's stock valued at $14,507,000 after purchasing an additional 341,009 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Liquidia during the 4th quarter valued at approximately $1,214,000. nVerses Capital LLC purchased a new stake in shares of Liquidia during the 4th quarter valued at approximately $335,000. Occudo Quantitative Strategies LP acquired a new position in Liquidia in the fourth quarter valued at approximately $3,107,000. Finally, Engineers Gate Manager LP lifted its holdings in Liquidia by 554.4% in the fourth quarter. Engineers Gate Manager LP now owns 101,848 shares of the company's stock valued at $3,513,000 after acquiring an additional 86,284 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA net product sales reached approximately $170.4 million, increasing 31% from the first quarter. Liquidia also reported about 5,900 unique prescriptions and more than 5,000 patients treated since the product’s June 2025 launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Liquidia posted $171.7 million in quarterly revenue, up 1,842% year over year, and net income of $74.7 million, or $0.74 per diluted share, compared with a $0.49-per-share loss in the prior-year period. Adjusted EBITDA was $96.3 million, marking the company’s fourth consecutive quarter of increasing profitability. Liquidia Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Cash and cash equivalents rose to $284.2 million at June 30, from $190.7 million at year-end 2025. The company is also advancing 10 clinical studies for YUTREPIA and L606 across existing and potential new indications.
• Neutral Sentiment: Institutional positioning was mixed: 177 investors added LQDA shares in their latest reported quarter, while 108 reduced holdings. BlackRock and State Street were among the notable buyers, although Citadel and TCG Crossover reduced positions.
• Negative Sentiment: Results were mixed relative to analyst expectations. Revenue exceeded the consensus estimate of $168.48 million, but diluted EPS was slightly below one estimate of $0.76, despite beating the Zacks estimate of $0.70. Liquidia Earnings Report
• Negative Sentiment: Insider trading data showed 116 insider sales versus only one purchase over the past six months, including sizable sales by senior executives. With LQDA trading near its 12-month high and at a very elevated price-to-earnings ratio, those transactions may reinforce investor concerns about valuation and profit-taking.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source